CC BY
4# Research Results in Pharmacology
Research Results in Pharmacology 9(4): 21-29 UDC: 615.212.7 DOI 10.18413/rrpharmacology.9.10051
3 Research Article
Aversion-related effects of kappa-opioid agonist U-50488 on neural activity and functional connectivity between amygdala, ventral tegmental area, prefrontal cortex, hippocampus, and nucleus accumbens
Konstantin Y. Kalitin1-2, Alexander A. Spasov1-2, Olga Y. Mukha1
1 Volgograd State Medical University, 1 Pavshikh Bortsov Sq., Volgograd 400131 Russia
2 Volgograd Medical Research Center, 1 Pavshikh Bortsov Sq., Volgograd 400131, Russia
Corresponding author: Olga Y. Mukha folay.myhal4ixigmail.com)
Academic editor: Mikhail Korokin ♦ Received 17 July 2023 ♦ Accepted 20 September 2023 ♦ Published 08 November 2023
Citation: Kalitin KY, Spasov AA, Mukha OY (2023) Aversion-related effects of kappa-opioid agonist U-50488 on neural activity and functional connectivity between amygdala, ventral tegmental area, prefrontal cortex, hippocampus, and nucleus accumbens. Research Results in Pharmacology 9(3): 21-29. https://doi.Org/10.18413/rrphannacology.9.10051
Abstract
Introduction: Among the various receptor systems in the brain, the opioid receptors have been the subject of extensive research due to their integral role in pain modulation, reward processing, and emotional regulation. The kappa-opioid receptor (KOR) system, in particular, stands apart due to its unique contribution to stress response, aversive behaviors, and dysphoric states. This paper aims to provide an understanding of the neural activity underlying the aversion-associated effects of the KOR agonist U-50488.
Materials and Methods: Rats underwent stereotaxic surgery to implant electrodes into the amygdala, ventral tegmental area, prefrontal cortex, hippocampus, and nucleus accumbens. The rats were subjected to conditioned place preference test to measure aversion to U-50488. After that, local field potential (LFP) recordings were made. LFP data were processed and analyzed using spectral and coherence analysis methods. A stepwise multiple linear regression was employed to identify the LFP features most significantly correlated with aversion to U-50488.
Results: The administration of U-50488 resulted in significant changes in LFP signals across multiple brain regions. These changes were particularly notable in the theta, gamma, and delta bands of brain waves (p<0.05). Theta and gamma activities were especially sensitive to the effects of U-50488. Connectivity calculations revealed shifts in coherence between brain regions, particularly highlighting the amygdala's involvement. While changes were also observed in the ventral tegmental area, prefrontal cortex, hippocampus, and nucleus accumbens (p<0.05), they contributed less to aversion. Using the stepwise multiple linear regression method, we established a final model with the 3 most significant variables: (1) coherence between the amygdala and medial prefrontal cortex, (2) coherence between the amygdala and hippocampus, and (3) theta power in the amygdala.
Conclusion: Overall, the data provided insights into how electrical neural activity mediates aversion in response to KOR activation. The results showed that the severity of aversion can be reasonably predicted (r=0.72±0.02, p=0.0099) using LFP band power and functional connectivity data. We concluded that the amygdala is a brain region that contributes the most to the KOR agonist-induced aversion.
Copyright Kalitin KY. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Graphical Abstract
Data Acquisition ^ Feature Extraction ^ Machine Learning
0 10 20 30 40 50
Spectral Analysis
VTA
XI 1X1X1 IX
□ □ Feature Selection
Coherence Analysis
160 180 200 220 240 Actual Value
Linear Regression
Keywords
selective kappa-opioid agonist, U-50488, aversion, dysphoria, amygdala, LFP analysis, coherence, machine learning
Introduction
Kappa-opioid receptors (KORs) are one of the four main classes of opioid receptors in the brain, alongside mu (|i). delta (5), and nociceptin (NOP) receptors. Historically, the focus of research on opioids has primarily been on the mu opioid receptors, largely due to their euphoric effects and role in pain management. The kappa opioid system and KOR agonists have gained significant attention due to their potential therapeutic applications and their distinctive aversive effects. The activation of KORs by selective agonists like U-50488 can produce anhedonia and stress-like responses (Page et al. 2019). The kappa opioid system is distinctive in its ability to mediate dysphoric, and anxiogenic effects, contrasting sharply with the euphoric responses typically associated with mu opioid activation (Khan et al. 2022). These aversive effects correlate with neural activity alterations in key brain regions implicated in emotional processing, reward, learning, and motivation. Central among these regions are the amygdala, ventral tegmental area (VTA), medial prefrontal cortex (mPFC), hippocampus, and the nucleus accumbens (NAc) (Liu et al. 2021; Lv et al. 2022; Salin et al. 2023).
While the full spectrum of U-50488's effects on brain function and neural circuits remains incompletely
understood, insights that bridge this gap can be gleaned from local field potential analyses. The study of LFP (as well as ECoG and EEG) offers a direct window into the network-level oscillatory activity of neuronal populations and yields valuable information about inter-regional interactions (Bressler 2021; Sysoev et al. 2022a). Examining the effects of kappa-opioid agonists on LFP in specific brain areas can give an understanding of the underlying mechanisms by which KOR influences behavior and cognition (Kalitin et al. 2018).
Based on limited data, it is hypothesized that KOR activation in particular by agonists like U-50488, can alter the synchronized activity or functional coupling between different brain regions (Coleman et al. 2021). There might be disrupted communication between the VTA and NAc, leading to reduced reward signals and hence the aversive effects. Enhanced connectivity between the amygdala and the prefrontal cortex can compromise top-down regulation of stress-related behavior and emotions.
Given the aforementioned context, the objective of this paper is to explore changes in LFP power and brain connectivity after kappa-opioid agonist administration. These changes can potentially serve as biomarkers of analgesic and aversive effects of novel compounds with kappa-opioid activity and provide critical insights into the pathways by which KOR agonists exert their effects. In
particular, this can help in the search for biased kappa-opioid agonists.
Materials and Methods
Experimental animals
Adult male Sprague Dawley rats (n=60), weighing 260280 g were used in these studies. Animals were individually housed, maintained in a 12 h light/12 h dark cycle environment with controlled temperature (22±2°C), and provided food and water ad libitum. All procedures complied with the Principles of Good Laboratory Practice (State Standard of the Russian Federation GOST 33647-2015) and the Order of the Ministry of Health and Social Development of the Russian Federation dated 1 April, 2016 No. 199n "On Approval of the Rules of Laboratory Practice". Experiment protocols were approved by the Regional Research Ethics Committee of Volgograd Region (registration number IRB00005839 I0RG0004900, Minutes No. 2022/096 of 21.01.2022).
Surgery
Rats under isoflurane anesthesia were positioned in a stereotaxic frame (SR-5R-HT; Narishige group, Japan). A single midline incision was made over the scalp and five holes, each with a diameter of 0.5 mm, were drilled through the skull for stereotaxic implantation of low impedance stainless steel electrodes (diameter = 0.1 mm). Stereotactic coordinates from bregma were: prelimbic cortex (PrL): anterior-posterior (AP) = +2.7 mm, mediallateral (ML) = 0.8 mm, dorsal-ventral (DV) = 3.8 mm; basolateral amygdala (BLA): AP = -2.2-3.6 mm, ML = 5-5.3 mm, DV = 8.8 mm; hippocampus (Hipp): AP = -4.9 mm, ML = 4.8 mm, DV = 6.0 mm; ventral tegmental area (VTA): AP = -5.2 mm, ML = 1.0 mm, DV = 8.4-8.8 mm; nucleus accumbens (NAc): AP = +1.8 mm, ML = 1.6 mm, DV = 7.3 mm.
For the intracerebroventricular (i.c.v.) administration of drugs, a 21-gauge stainless steel guide cannula was implanted into the right lateral ventricle. Two stainless steel screws and dental polymer (Protacryl-M; Stoma, Ukraine) were used to secure the cannulas and electrodes to the skull surface.
LFP recordings
The experiments were conducted 5 days after surgery. LFP activity was recorded in a monopolar montage using a laboratory electroencephalograph NVX-36 (MCS, Russia). Signals were digitized at a sampling rate of 500 Hz. Following a 10-min baseline recording, animals underwent lateral i.c.v. injection with ACSF 5 ^L (control group) and U-50488 (100 ^g in 5 ^L, Sigma-Aldrich, USA). Thirty minutes following compound administration, LFP activity was recorded for 10 minutes.
Conditioned place preference test
The conditioning apparatus (Open Science, Russia) consisted of three chambers. Two conditioning compartments (30x30x40 cm) were distinguishable by visual and tactile cues, and a smaller middle chamber (12x30x40 cm). The test consisted of three phases: preconditioning (one session), conditioning (six sessions), and post-conditioning (one session). All these sessions were conducted over 5 consecutive days (two conditioning sessions per day).
During the pre-conditioning phase (Day 1), the animals were placed into the CPP apparatus and were allowed free access to both conditioning chambers of the apparatus for 15 minutes.
During the conditioning phase (Days 2-4), the animals received i.c.v. injections of either ACSF (5 ^L) or U-50488 (100 ^g/rat) and were confined to one side of the CPP apparatus for 30 minutes. Four hours later, the rats were administered the alternate treatment and immediately confined to the opposite compartment for 30 minutes. In each group, 50% of the rats were initially placed in the preferred chamber, while the remaining 50% were placed in the non-preferred chamber.
On the final day (post-conditioning), the animals had unrestricted access to all compartments for 15 minutes. Preference change was quantified as the difference (in seconds) between the time spent in the U-50488-associated compartment on the post-conditioning day and the time spent in the same compartment on the preconditioning day.
The unpaired t-test was employed for comparing groups. Statistical significance was accepted at the level p<0.05.
LFP signal analysis
Processing the LFP data involved several stages including initial data cleaning, referencing, and the removal of muscle activity artifacts using independent component analysis (ICA). Subsequently, the LFP signals underwent bandpass filtering (0.5-50 Hz) with a linear finite impulse response (FIR) filter. Spectral analysis was performed by fast Fourier transformation (FFT) in Python. Frequency bands were defined as delta 0.5-4 Hz, theta 4-8 Hz, alpha 8-12 Hz, beta 12-30 Hz, and gamma 30-50 Hz.
The intra-hemispheric coherence between each pair of electrodes was analyzed in 1-second epochs. For each period, the magnitude squared coherence for each channel was calculated with the mscohere function (parameters: window = 1 s, noverlap, nfft = 500, fs = 500) built in MATLAB. The analysis of the data was performed only for the theta (4-8 Hz) frequency band. We chose the theta band of the spectrum for analysis based on the preliminary studies in which we observed the most pronounced changes within this frequency range. To normalize the data and conduct parametric statistical tests, we applied the Fisher z-transformation to all correlation coefficients.
The significance of differences among the groups was evaluated with unpaired t-test using GraphPad Prism 9.5. The criterion used to reject the null hypotheses was p<0.05.
Regression analysis
One data sample included 35 predictors (5 electrodes for power values x 5 frequency bands + 10 electrode pairs for coherence) and 1 dependent variable (directly observable behavior in the CPP test as a measure of aversion severity).
As the collected data included too many predictors and due to concern regarding over-fitting (severe deterioration of prediction accuracy when a model is applied to novel datasets) we employed a backward variable selection method. The stepwise multiple linear regression method was utilized for dimensionality reduction and identifying the most correlated LFP measures of aversion in rats. The stepwise multiple linear regression is a machine learning approach that iteratively removes predictors from the model based on the
significant/insignificant main effects on the regression model. In this model, the LFP power and coherence were the predictor variables and the aversion score (time difference obtained from CPP) was the response variable.
The five-fold cross-validation was repeated for 100 iterations. The resulting performance was calculated as the mean performance of all iterations and folds. To determine whether the observed correlation was significantly different from what might be expected by chance, we conducted a permutation test by permuting the aversion scores of rats 100 times. In each permutation, we randomly shuffled the aversion scores and then we repeated the cross-validation procedure
explained above including all the steps of the training and testing. For each permutation, the mean absolute error (MAE) and the R2 (coefficient of determination) values, averaged across folds, were obtained. Then, a permutation-based p-value was computed by dividing the number of times the shuffled value was greater than the true MAE value by 100 (the number of iterations).
Results
As depicted in Fig. 1A-E, the administration of U-50488 (100 p,g/rat i.c.v.) produced complex changes in LFP
Figure 1. Power spectral density of LFP signals recorded from 30 to 40 min post-administration of U-50488 (100 ^g/rat, i.c.v.) in the (A) medial prefrontal cortex (mPFC), (B) amygdala (Amy), (C) hippocampus (Hipp), (D) ventral tegmental area (VTA), and (E) nucleus accumbens (NAc), plotted as a function of frequency. Each graph presents the averaged power spectral density for both control and U-50488 groups. The solid traces depict the mean and the shading indicates ±SEM. Significant differences (p<0.05) are represented by gray shaded areas in each plot. (F) Chord diagram shows statistically significant changes (p<0.05) in LFP coherence from baseline in theta frequency range after U-50488 treatment. Red color represents increases and blue color indicates decreases in coherence.
signals recorded from all channels. Statistical analysis indicated that U-50488 significantly enhanced the power of theta band in the prefrontal cortex, amygdala, and nucleus accumbens between 30 and 40 minutes postinjection (p<0.05). The compound also increased delta power in the prefrontal cortex while it decreased gamma band power in the prefrontal cortex, amygdala, ventral tegmental area, and nucleus accumbens (p<0.05). Additionally, a decrease in the power of beta frequencies was observed in the signals recorded from the prefrontal cortex and nucleus accumbens (p<0.05). Among the brain waves, theta and gamma activity were found to be the most sensitive to U-50488 administration.
To delve deeper into the relationships between oscillatory LFP activity in the mPFC, Amy, Hipp, VTA, and NAc, network connectivity was calculated. The mean coherence changes in the 4-8 Hz band for combinations of brain recordings that are statistically different from the control group (p<0.05) are presented in Fig. 1F. In these 10 independent analyses, the results were consistent. There was a significant increase in coherence in six combinations, whereas a decrease was observed in only two connections, both of which involved the amygdala.
Administration of U-50488 resulted in a significant aversive response in the CPP test compared to the control group (p<0.05). Immediately after post-conditioning, we recorded LFP signals. A multiple linear regression model was constructed using the backward variable selection method to identify the most significant features of the LFP signals associated with aversion.
Based on the analysis, three variables were found to have the highest predictive power: (1) coherence between the amygdala and medial prefrontal cortex, (2) coherence between the amygdala and hippocampus, and (3) theta power in the amygdala. Notably, all three predictors were related to amygdala.
As can be seen in Fig. 2, the predicted values for aversion were in good agreement with the actual values. Here we applied 5-fold cross-validation to validate our results. Our findings reveal a positive significant correlation of r = 0.72±0.02, between the actual and the predicted values, with R-squared = 0.18±0.08, MAE = 11.69±0.08 with p = 0.0099 (Fig. 2A-B).
Discussion
Kappa-opioid receptors are widely distributed throughout the brain. Activation of KORs by U-50488 and other kappa-opioid agonists has been shown to produce aversive effects in animal models and humans, suggesting a role for KORs in the modulation of aversion. However, the precise neural mechanisms and functional interactions underlying these effects remain poorly understood.
The pharmaco-EEG approach enables the effective detection of antipsychotic, neuroprotective, and other psychotropic activities (Kalitin et al. 2022a; Sysoev et al. 2022b). In particular, we previously observed specific changes in rat electroencephalogram (EEG) following the administration of kappa-opioid agonists (butorphanol and RU-1205) during global cerebral ischemia (Kalitin et al. 2022b).
An EEG study in humans showed a significant increase in delta and gamma ranges and a decrease in alpha oscillatory activity when subjects were under the effect of kappa-opioid agonist salvinorin A (Ona et al. 2022). In another study, salvinorin A administration induced a reduction in beta-frequency spectral power range (13-29 Hz) at midline electrode sites in healthy humans (Ranganathan et al. 2012).
An increase in the power spectral density in the anterior region (in all frequency bands) and
Figure 2. (A) Linear correlation plot between actual and predicted values of aversion for the whole dataset. Predictors selected for the multiple linear regression model: Amy-mPFC coherence, Amy-Hipp coherence and LFP theta power in Amy (all p<0.05). The right-hand margin histogram provides a depiction of the distribution of predicted values, while the top margin histogram illustrates the distribution of actual values. (B) Represents the graph of residuals vs. predicted values where the prediction made by the model is on the x-axis and the accuracy of that prediction is on the y-axis. The residuals are symmetrically distributed around zero. Histograms in the upper and right margins represent the distributions of predicted values and residuals.
an insignificant decrease in the posterior region were observed after the administration of Salvia divinorum extract in rats (Simon-Arceo et al. 2017).
In conscious rats, kappa-opioid agonists - in particular spiradoline, enadoline, BRL 52656, and BRL 53001 - were demonstrated to induce a decrease in EEG power within the theta band (4-7 Hz) (Coltro Campi and Clarke 1995).
Electrocorticographic (ECoG) effects of kappa opioids enadoline and PD117302 were studied in conscious, freely moving rats. Spectral analysis revealed a decrease in power in the 0-4 Hz band, coupled with an increase in the 4-8 Hz frequency range. The peak ECoG frequencies were 5.0 Hz and 4.8 Hz for enadoline and PD117302, respectively. There was also a significant shift in the mean EEG frequency from 6.6 Hz to 6.2 Hz after drug administration. Additionally, the drugs resulted in decreased edge frequency, mobility, and complexity of the EEG (Tortella et al. 1997).
Our data generally agree with prior findings. However, several issues regarding past research should be acknowledged: a) the majority of the referenced studies are dated; b) the existing research focuses solely on signals recorded from the cerebral cortex; c) direct effects of kappa-opioid agonists on functional connectivity are not documented; d) it remains undetermined which specific brain wave changes are related to aversive effects and which are associated with other effects, such as analgesic activity.
In Table 1, we provide data on LFP changes across various brain regions depending on aversive effects, including anhedonia, anxiety, depression, and sedation. The majority of the changes are nonspecific, and there are a substantial amount of conflicting results in the literature. Furthermore, the changes can vary based on the underlying cause of the aversive effect. At present, it remains unclear whether these changes will be induced by KOR agonists.
Table 1. Electrophysiological changes associated with aversive psycho-emotional states in various brain regions
Brain area
Anhedonia
Anxiety/fear
Depression
Sedation
Amygdala Increased firing rate of central
nucleus of the amygdala (Wang et al. 2016)
Increased BLA cell firing <1 Hz (Reznikov et al. 2018)
Enhanced theta-gamma coupling (Stujenske et al. 2014)
Increased low theta waves and gamma frequencies (Merino et al. 2021)
Faster firing of projection neurons in the stress-exposed group compared to controls (Neves and Grace 2019)
ND
VTA
VTA GABA neurons drive low frequency NAc LFP oscillations, rhythmically modulating NAc firing rates (Lowes et al. 2021) Decreased activity of VTA DA neurons (Markovic et al. 2021)
VTA DA cells baseline firing rate lowering (Corral-Frias et al. 2013; Guan et al. 2022)
Double or triple peaks at frequencies of 1-8 Hz and additional peaks at frequencies of 4-8 Hz (Friedman et al. 2012)
Reduced VTA GABA neuron firing rate and converted their activity into phasic 0.5-2.0 sec ON/OFF periods (Lee et al. 2001)
PFC
Reduced frequencies of spontaneous and miniature IPSCs Decreased release probability of perisomatic-targeting GABAergic synapses and alterations in GABAB receptor mediated signaling (Czeh et al. 2018)
Increases in both theta-frequency power in the mPFC and theta-frequency synchronization between the mPFC and ventral hippocampus (Sang et al. 2018)
Reduction in beta and gamma power (Jia et al. 2019)
Beta/low gamma (12-40 Hz) LFP power increased (Guidera et al. 2017)
Hippocampus Decrease in spontaneous firing activity (Bambico et al. 2009) Reduction in theta energy and increase in gamma energy in the dentate gyrus region of the hippocampus. Attenuation of theta rhythm synchronization between perforant path and dentate gyrus and weakened theta-gamma cross-frequency coupling (Zhao et al. 2022)
Reduction in beta and gamma power (Jia et al. 2019) Increase in low theta and gamma frequencies (Merino et al. 2021)
Two spectral peaks, one in the theta range, the other at higher frequencies (25-50 Hz) (Soltesz and Deschênes 1993)
NAc
Reduced electrical excitability of NAcSh neurons (Wallace et al. 2009)
Increased LFP power in the theta frequency range (4-12 Hz) (Okonogi and Sasaki 2021)
Decrease in spontaneous firing rate (Crofton et al. 2017) Decreased magnitude of excitatory synaptic transmission (Wang et al. 2010) Decreased alpha, beta and low gamma LFP oscillatory activity (Voget et al. 2015)
Increase in EEG power of slow frequencies (4-6 Hz) (Slawecki 2002)
Note: basolateral amygdala (BLA); dopamine (DA); electroencephalogram (EEG); inhibitory postsynaptic currents (IPSCs); medial prefrontal cortex (mPFC); local field potential (LFP); nucleus accumbens shell (NAcSh); no data (ND); ventral tegmental area (VTA).
The use of deep electrodes greatly enhanced our understanding of the brain's electrical activity reorganization in response to compound U-50488. The changes we detected were consistent with the known side effects of kappa-opioid agonists. It should be noted that in this study both acute and chronic effects of U-50488 were observed, as the substance was administered regularly over a four-day conditioning period.
During our analysis we focused on quantifying aversion heterogeneity in terms of brain electrical activity and connectivity, rather than classifying data into binary categories. We avoided binary classification, as it offers limited insights into aversion heterogeneity and does not effectively test the potential continuum between severe and mild aversive states. Thus, we used the aversion levels obtained from the CPP to construct a predictive model based on LFP signal power. Furthermore, we integrated our analysis with connectome-based predictive modeling by taking into account the coherence data. The connectome-based predictive modeling is a recently developed method for identifying and modeling a brain network associated with a variable of interest, the aversion severity in our case (Ren et al. 2021). Connectome-based predictive modeling was previously employed in a number of studies to predict network alteration in several brain disorders such as anxiety related illnesses and sleep disorders as well in some other conditions such as creativity and personality traits (Kabbara et al. 2022).
We hypothesized that combining multiple LFP variables would predict aversion more accurately than a single variable, given the association of several brain regions and various frequency bands with aversion (Table 1). Using the backward variable selection method, we got a final model with the three most significant variables, all of which involved the amygdala. The findings align with previous data indicating the central role of the amygdala in mediating aversive reactions (O'Neill PK et al. 2018). The information obtained may be particularly useful in the
References
■ Bambico FR, Nguyen NT, Gobbi G (2009) Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress. European Neuropsychopharmacology 19(3): 215228. https://doi.org/10.1016/j.euroneuro.2008.11.005 [PubMed]
■ Bressler SL (2021) Directed Interregional Brain Interactions. In: Diwadkar VA, B Eickhoff S (Eds) Brain Network Dysfunction in Neuropsychiatric Illness. Springer, Cham, 75-92. https://doi.org/ 10.1007/978-3-030-59797-9_4
■ Coleman BC, Manz KM, Grueter BA (2021) Kappa opioid receptor modulation of excitatory drive onto nucleus accumbens fast-spiking interneurons. Neuropsychopharmacology 46(13): 2340-2349. https://doi.org/10.1038/s41386-021-01146-8 [PubMed] [PMC]
■ Coltro Campi C, Clarke GD (1995) Effects of highly selective kappa-opioid agonists on EEG power spectra and behavioural correlates in conscious rats. Pharmacology, Biochemistry, and Behavior 51(4): 611-616. https://doi.org/ 10.1016/0091-3057(94)00384-u [PubMed]
Corral-Frias NS, Lahood RP, Edelman-Vogelsang KE, French ED, Fellous JM (2013) Involvement of the ventral tegmental area in a rodent model of post-traumatic stress disorder. Neuropsychopharmacology 38(2): 350-363. https://doi.org/10.1038/ npp.2012.189 [PubMed] [PMC]
■ Crofton EJ, Nenov MN, Zhang Y, Scala F, Page SA, McCue DL, Li D, Hommel JD, Laezza F, Green TA (2017) Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell. Neuropharmacology 117: 49-60. https://doi.org/10.1016/ j.neuropharm.2017.01.020 [PubMed] [PMC]
study of biased kappa-opioid agonists.
Conclusions
In the study, the administration of U-50488 led to significant changes in LFP signals across multiple brain regions. These changes were particularly notable in the theta, gamma, and delta bands of brain waves. Among these, theta and gamma activities were especially sensitive to the effects of U-50488. Connectivity calculations revealed shifts in coherence between different brain regions, particularly highlighting the amygdala's involvement. While changes were also observed in the ventral tegmental area, prefrontal cortex, hippocampus, and nucleus accumbens, they were less significant in relation to aversion.
Using the stepwise multiple linear regression method, we established the final model with the 3 most significant variables linked to the amygdala, reaffirming its central role in aversive responses. It was suggested that combined metrics might predict aversion more accurately than single variables. Overall, the data revealed insights into how kappa-opioid receptors, which are found throughout the brain, influence aversion.
Funding
The authors have no funding to report.
Conflict of interests
The authors declare no conflict of interests.
Acknowledgments
The authors have no support to report.
■ Czeh B, Vardya I, Varga Z, Febbraro F, Csabai D, Martis LS, H0jgaard K, Henningsen K, Bouzinova EV, Miseta A, Jensen K, Wiborg O (2018) Long-term stress disrupts the structural and functional integrity of gabaergic neuronal networks in the medial prefrontal cortex of rats. Frontiers in Cellular Neuroscience 12: 148. https://doi.org/10.3389/fncel.2018.00148 [PubMed] [PMC]
■ Friedman A, Lax E, Abraham L, Tischler H, Yadid G (2012) Abnormality of VTA local field potential in an animal model of depression was restored by patterned DBS treatment. European Neuropsychopharmacology 22(1): 64-71. https://doi.org/10.1016/ j.euroneuro.2011.04.005 [PubMed]
■ Guan P, Huang C, Lan Q, Huang S, Zhou P, Zhang C (2022) Activation of ventral tegmental area dopaminergic neurons ameliorates anxiety-like behaviors in single prolonged stress-induced PTSD model rats. Neurochemistry International 161: 105424. https://doi.org/10.1016/j.neuint.2022.105424 [PubMed]
■ Guidera JA, Taylor NE, Lee JT, Vlasov KY, Pei J, Stephen EP, Mayo JP, Brown EN, Solt K (2017) Sevoflurane induces coherent slow-delta oscillations in rats. Frontiers in Neural Circuits 11: 36. https:// doi.org/10.3389/fncir.2017.00036 [PubMed] [PMC]
■ Jia L, Sun Z, Shi D, Wang M, Jia J, He Y, Xue F, Ren Y, Yang J, Ma X (2019) Effects of different patterns of electric stimulation of the ventromedial prefrontal cortex on hippocampal-prefrontal coherence in a rat model of depression. Behavioural Brain Research 356: 179188. https://doi.org/10.1016/j.bbr.2018.08.032 [PubMed]
Kabbara A, Robert G, Khalil M, Verin M, Benquet P, Hassan M (2022) An electroencephalography connectome predictive model of major depressive disorder severity. Scientific Reports 12(1): 6816.
https://doi.org/10.1038/s41598-022-10949-8 [PubMed] [PMC]
■ Kalitin KY, Grechko OY, Spasov AA, Sukhov AG, Anisimova VA, Matukhno AE (2018) GABAergic mechanism of anticonvulsive effect of chemical agent RU-1205. Bulletin of Experimental Biology and Medicine 164(5): 629-635. https://doi.org/10.1007/s10517-018-4047-4 [PubMed]
■ Kalitin KY, Pridvorov GV, Spasov AA, Mukha OY (2022a) Effect of clozapine and 5-nt2a-antagonist ru-31 on electroencephalography and motor activity of rats in a model of schizophrenia with neonatal destruction of the ventral hippocampus. Kuban Scientific Medical Bulletin [Kubanskiy Nauchnyy Meditsinskiy Vestnik] 29(5): 108-122. https://doi.org/10.25207/1608-6228-2022-29-5-108-122 [in Russian]
■ Kalitin KY, Pridvorov GV, Spasov AA, Mukha OY (2022b) Neuroprotective action of butorphanol and RU-1205 with evaluation of their effect on the bioelectrical activity of the brain in the global ischemia model. Journal of Volgograd State Medical University [Vestnik Volgogradskogo Gosudarstvennogo Meditsinskogo Universiteta] 19(3): 128-133. https://doi.org/10.19163/1994-9480-2022-19-3-128-133 [in Russian]
■ Kawashima I, Kumano H (2017) Prediction of mind-wandering with electroencephalogram and non-linear regression modeling. Frontiers in Human Neuroscience 11: 365. https://doi.org/10.3389/ fnhum.2017.00365 [PubMed] [PMC]
■ Khan MIH, Sawyer BJ, Akins NS, Le HV (2022) A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse. European Journal of Medicinal Chemistry 243: 114785. https://doi.org/10.1016/ j.ejmech.2022.114785 [PubMed]
■ Lee RS, Steffensen SC, Henriksen SJ (2001) Discharge profiles of ventral tegmental area GABA neurons during movement, anesthesia, and the sleep-wake cycle. The Journal of Neuroscience 21(5): 17571766. https://doi.org/10.1523/jneurosci.21-05-01757.2001 [PubMed] [PMC]
■ Liu R Wang Y, Chen X, Zhang Z, Xiao L, Zhou Y (2021) Anhedonia correlates with functional connectivity of the nucleus accumbens subregions in patients with major depressive disorder. NeuroImage: Clinical 30: 102599. https://doi.org/10.1016/j.nicl.2021.102599 [PubMed] [PMC]
■ Lowes DC, Chamberlin LA, Kretsge LN, Holt ES, Abbas AI, Park AJ, Yusufova L, Bretton ZH, Firdous A, Enikolopov AG, Gordon J A Harris AZ (2021) Ventral tegmental area GABA neurons mediate stress-induced blunted reward-seeking in mice. Nature Communications 12(1): 3539. https://doi.org/10.1038/s41467-021-23906-2 [PubMed] [PMC]
■ Lv X, Zhang X, Zhao Q, Li C, Zhang T, Yang X (2022) Acute stress promotes brain oscillations and hippocampal-cortical dialog in emotional processing. Biochemical and Biophysical Research Communications 598: 55-61. https://doi.org/10.1016/j.bbrc.2022.01.116 [PubMed]
■ Markovic T, Pedersen CE, Massaly N, Vachez YM, Ruyle B, Murphy CA, Abiraman K, Shin JH, Garcia JJ, Yoon HJ, Alvarez VA, Bruchas MR, Creed MC, Morón JA (2021) Pain induces adaptations in ventral tegmental area dopamine neurons to drive anhedonia-like behavior. Nature Neuroscience 24(11): 1601-1613. https://doi.org/10.1038/ s41593-021-00924-3 [PubMed] [PMC]
■ Merino E, Raya-Salom D, Teruel-Martí V, Adell A Cervera-Ferri A Martínez-Ricós J (2021) Effects of acute stress on the oscillatory activity of the hippocampus-amygdala-prefrontal cortex network. Neuroscience 476: 72-89. https://doi.org/10.1016/ j.neuroscience.2021.09.009 [PubMed]
■ Neves GA Grace AA (2019) al nicotinic receptor full agonist reverse basolateral amygdala hyperactivity and attenuation of dopaminergic neuron activity in rats exposed to chronic mild stress. European Neuropsychopharmacology 29(12): 1343-1353. https://doi.org/10.1016/ j.euroneuro.2019.09.009 [PubMed] [PMC]
■ Okonogi T, Sasaki T (2021) Theta-range oscillations in stress-induced mental disorders as an oscillotherapeutic target. Frontiers in Behavioral Neuroscience 15: 698753. https://doi.org/10.3389/fnbeh.2021.698753 [PubMed] [PMC]
■ Ona G, Sampedro F, Romero S, Valle M, Camacho V, Migliorelli C, Mañanas MÁ, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, Riba J (2022) The Kappa opioid receptor and the sleep of reason: Cortico-subcortical imbalance following salvinorin-A. The International Journal of Neuropsychopharmacology 25(1): 54-63. https://doi.org/10.1093/ijnp/pyab063 [PubMed] [PMC]
■ O'Neill PK, Gore F, Salzman CD (2018) Basolateral amygdala circuitry in positive and negative valence. Current Opinion in
Neurobiology 49: 175-183. https://doi.org/10.1016/ j.conb.2018.02.012 [PubMed] [PMC]
■ Page S, Mavrikaki MM, Lintz T, Puttick D, Roberts E, Rosen H, Carroll FI, Carlezon WA, Chartoff EH (2019) Behavioral pharmacology of novel kappa opioid receptor antagonists in rats. The International Journal of Neuropsychopharmacology 22(11): 735-745. https://doi.org/10.1093/ijnp/pyz054 [PubMed] [PMC]
■ Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the k opioid agonist Salvinorin A in humans. Biological Psychiatry 72(10): 871879. https://doi.org/10.1016/j.biopsych.2012.06.012 [PubMed] [PMC]
■ Ren Z, Daker RJ, Shi L, Sun J, Beaty RE, Wu X, Chen Q, Yang W, Lyons IM, Green AE, Qiu J (2021) Connectome-based predictive modeling of creativity anxiety. Neuroimage 225: 117469. https:// doi.org/10.1016/j.neuroimage.2020.117469 [PubMed]
■ Reznikov R, Bambico FR, Diwan M, Raymond RJ, Nashed MG, Nobrega JN, Hamani C (2018) Prefrontal cortex deep brain stimulation improves fear and anxiety-like behavior and reduces basolateral amygdala activity in a preclinical model of posttraumatic stress disorder. Neuropsychopharmacology 43(5): 1099-1106. https://doi.org/10.1038/npp.2017.207 [PubMed] [PMC]
■ Salin A, Dugast E, Lardeux V, Solinas M, Belujon P (2023) The amygdala-ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine. British Journal of Pharmacology 180(14): 1819-1831. https://doi.org/10.1111/ bph.16034 [PubMed]
■ Sang K, Bao C, Xin Y, Hu S, Gao X, Wang Y, Bodner M, Zhou YD, Dong XW (2018) Plastic change of prefrontal cortex mediates anxiety-like behaviors associated with chronic pain in neuropathic rats. Molecular Pain 14: 1744806918783931. https://doi.org/ 10.1177/1744806918783931 [PubMed] [PMC]
■ Simon-Arceo K, Gonzalez-Trujano ME, Coffeen U, Fernandez-Mas R, Mercado F, Almanza A, Contreras B, Jaimes O, Pellicer F (2017) Neuropathic and inflammatory antinociceptive effects and electrocortical changes produced by Salvia divinorum in rats. Journal of Ethnopharmacology 206: 115-124. https://doi.org/ 10.1016/j.jep.2017.05.016 [PubMed]
■ Slawecki CJ (2002) Altered EEG responses to ethanol in adult rats exposed to ethanol during adolescence. Alcoholism, Clinical and Experimental Research 26(2): 246-254. [PubMed]
■ Soltesz I, Deschenes M (1993) Low- and high-frequency membrane potential oscillations during theta activity in CA1 and CA3 pyramidal neurons of the rat hippocampus under ketamine-xylazine anesthesia. Journal of Neurophysiology 70(1): 97-116. https:// doi.org/10.1152/jn.1993.70.1.97 [PubMed]
■ Stujenske JM, Likhtik E, Topiwala MA, Gordon JA (2014) Fear and safety engage competing patterns of theta-gamma coupling in the basolateral amygdala. Neuron 83(4): 919-933. https://doi.org/ 10.1016/j.neuron.2014.07.026 [PubMed] [PMC]
■ Sysoev YI, Prikhodko VA, Idiyatullin RD, Chemyakov RT, Karev VE, Okovityi SV (2022a) A method for chronic registration of brain cortical electrical activity in rats. Journal of Evolutionary Biochemistry and Physiology 58(1): 292-301. https://doi.org/ 10.1134/S0022093022010252
■ Sysoev YI, Prikhodko VA, Shits DD, Puchik MM, Okovityi SV (2022b) Application of the method of pharmacoencephalography for the assessment of neuroprotective drug activity. Bulletin of Perm University. Biology 4: 347-35 1. https://doi.org/ 10.17072/1994-9952-2022-4-347-351
■ Tortella FC, Rose J, Robles L, Moreton JE, Hughes J, Hunter JC (1997) EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. The Journal of Pharmacology and Experimental Therapeutics 282(1): 286-293. [PubMed]
■ Voget M, Rummel J, Avchalumov Y, Sohr R, Haumesser JK, Rea E, Mathe AA, Hadar R, van Riesen C, Winter C (2015) Altered local field potential activity and serotonergic neurotransmission are further characteristics of the Flinders sensitive line rat model of depression. Behavioural Brain Research 291: 299-305. https:// doi.org/10.1016/j.bbr.2015.05.027 [PubMed]
■ Wallace DL, Han MH, Graham DL, Green TA, Vialou V, Iniguez SD, Cao JL, Kirk A, Chakravarty S, Kumar A, Krishnan V, Neve RL, Cooper DC, Bolanos CA, Barrot M, McClung CA, Nestler EJ (2009) CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nature Neuroscience 12(2): 200-209. https://doi.org/10.1038/nn.2257 [PubMed] [PMC]
■ Wang L, Shen M, Jiang C, Ma L, Wang F (2016) Parvalbumin interneurons of central amygdala regulate the negative affective states and the expression of corticotrophin-releasing hormone during morphine withdrawal. The International Journal of Neuropsychopharmacology 19(11): 1-12. https://doi.org/10.1093/ ijnp/pyw060 [PubMed] [PMC]
■ Wang W, Sun D, Pan B, Roberts CJ, Sun X, Hillard CJ, Liu QS (2010) Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 35(11): 2249-2261. https://doi.org/ 10.1038/npp.2010.99 [PubMed] [PMC]
■ Young GA, Hudson GM, Stamidis H, Steinfels GF (1993) Interactions between U-50,488H and sigma receptor antagonists: EEG, EEG power spectral and behavioral correlates. European Journal of Pharmacology 231(3): 473476. http s://doi.org/10.1016/0014-2999(93)90127-4 [PubMed]
■ Zhao S, Xu X, Xie G, Zhang T (2022) Chronic corticosterone exposure impairs emotional regulation and cognitive function through disturbing neural oscillations in mice. Behavioural Brain Research 434: 114030. https://doi.org/10.1016/j.bbr.2022.114030 [PubMed]
Author Contributions
■ Konstantin Y. Kalitin, PhD, Associate Professor of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; Senior Researcher, Laboratory of Metabotropic Drugs, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia; Researcher, Laboratory of experimental pharmacology, Volgograd Medical Research Center, Volgograd, Russia; e-mail: [email protected]; ORCID ID https://orcid.org/0000-0002-0079-853X. Conceptualization, setting primary objectives, carrying out experimental procedures, literature review, analyzing and interpreting the data, writing the initial draft of the article, contributing to the overall structure and design, finalizing the article for submission, designing visual data representations, applying statistical, mathematical, and computational methods for data analysis.
■ Alexander A. Spasov, PhD, Professor, Academician of the Russian Academy of Sciences; Head of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; Head of the Laboratory of experimental pharmacology, Volgograd Medical Research Center, Volgograd, Russia; Head of the Department of Pharmacology and Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia; e-mail: [email protected]; ORCID ID https://orcid.org/0000-0002-7185-4826. Concept statement, supervision and mentorship, workflow control, critical revision with valuable intellectual investment, contributing to the overall structure and design, ensuring the integrity and consistency of the entire article.
■ Olga Y. Mukha, Teaching fellow of the Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Volgograd, Russia; e-mail: [email protected]; ORCID ID https://orcid.org/ 0000-0002-0429-905X. Task management, experimental work, literature review, data collection, drafting the manuscript, contributing to the scientific layout, ensuring the integrity and consistency of the entire article, including its final version, application of statistical, mathematical, and computational methods for data analysis, preparation of the final manuscript, interaction with the editors and reviewers.
